View Future GrowthAnanda Pharma 과거 순이익 실적과거 기준 점검 0/6Ananda Pharma 의 수입은 연평균 -47.5%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 97.8%의 비율로 증가해 왔습니다.핵심 정보-47.51%순이익 성장률-8.32%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률97.80%자기자본이익률-1,527.35%순이익률-101,771.51%최근 순이익 업데이트31 Jul 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United KingdomNew Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$1.0k). Minor Risks Latest financial reports are more than 6 months old (reported July 2024 fiscal period end). Market cap is less than US$100m (€16.6m market cap, or US$18.5m).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$935). Minor Risk Market cap is less than US$100m (€21.7m market cap, or US$22.4m).공시 • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.0m).공시 • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (€14.9m market cap, or US$16.6m).공시 • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United KingdomNew Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€9.10m market cap, or US$9.61m).공시 • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom공시 • Dec 20Ananda Developments plc Announces Board ChangesAnanda Developments Plc announced that Stuart Piccaver, the Chief Executive Officer of JEPCO and a director of Anglia Salads, has been appointed as an executive Director of Company. With a background and interest in marketing and innovation, Mr. Piccaver has considerable horticultural experience and direct experience of Cannabis cultivation. Dr. Inbar Pomeranchik, who was previously an executive Director, has become a Non-executive Director of the Company, also with effect from December 19, 2022.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jul 21Ananda Developments Plc, Annual General Meeting, Aug 17, 2022Ananda Developments Plc, Annual General Meeting, Aug 17, 2022, at 09:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United KingdomBoard Change • Jun 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.매출 및 비용 세부 내역Ananda Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:1FX 매출, 비용 및 순이익 (GBP Millions)날짜매출순이익일반관리비연구개발비31 Jul 250-54030 Apr 250-43031 Jan 250-43031 Oct 240-52031 Jul 240-62030 Apr 240-62031 Jan 240-62031 Oct 230-42031 Jul 230-21030 Apr 230-21031 Jan 230-11031 Oct 220-11031 Jul 220-11030 Apr 220-11031 Jan 220-11031 Oct 210-11031 Jul 210-11030 Apr 210-11031 Jan 21000031 Oct 20000031 Jul 20000030 Apr 20000031 Jan 20000031 Oct 19000031 Jul 190-11030 Apr 190-110양질의 수익: 1FX 은(는) 현재 수익성이 없습니다.이익 마진 증가: 1FX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1FX은 수익성이 없으며 지난 5년 동안 손실이 연평균 47.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 1FX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 1FX은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 1FX는 현재 수익성이 없으므로 자본 수익률이 음수(-1527.35%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 05:50종가2026/05/27 00:00수익2025/07/31연간 수익2025/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ananda Pharma Plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.
공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$1.0k). Minor Risks Latest financial reports are more than 6 months old (reported July 2024 fiscal period end). Market cap is less than US$100m (€16.6m market cap, or US$18.5m).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$935). Minor Risk Market cap is less than US$100m (€21.7m market cap, or US$22.4m).
공시 • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035
New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.0m).
공시 • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.
New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (€14.9m market cap, or US$16.6m).
공시 • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United Kingdom
New Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).
New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€9.10m market cap, or US$9.61m).
공시 • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom
공시 • Dec 20Ananda Developments plc Announces Board ChangesAnanda Developments Plc announced that Stuart Piccaver, the Chief Executive Officer of JEPCO and a director of Anglia Salads, has been appointed as an executive Director of Company. With a background and interest in marketing and innovation, Mr. Piccaver has considerable horticultural experience and direct experience of Cannabis cultivation. Dr. Inbar Pomeranchik, who was previously an executive Director, has become a Non-executive Director of the Company, also with effect from December 19, 2022.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jul 21Ananda Developments Plc, Annual General Meeting, Aug 17, 2022Ananda Developments Plc, Annual General Meeting, Aug 17, 2022, at 09:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United Kingdom
Board Change • Jun 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.